Skip to content

Study · Animal study (in vivo) · mouse · 2008

11 results

Exendin-4 modulates diabetes onset in nonobese diabetic mice.

Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ

Endocrinology6 Dec 2007Cited by 91 (Europe PMC)

PMID18063685 (opens in a new tab)PMCIDPMC2275367 (opens in a new tab)DOI10.1210/en.2007-1137 (opens in a new tab)PepBankPUB-18063685
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 begun at 4 weeks of age delayed diabetes onset.

    In plain wordsIn mice prone to diabetes, exendin‑4 started early delayed diabetes onset.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDiabetes onset
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 microg twice daily · 26 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Ex-4 treatment for 26 wk (2 microg twice daily) initiated at 4 wk of age delayed the onset of diabetes (P = 0.007).
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 reduced insulitis scores.

    In plain wordsIn mice prone to diabetes, exendin‑4 reduced pancreatic islet inflammation scores.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulitis score
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced beta-cell mass, and improved glucose tolerance.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 increased beta-cell mass.

    In plain wordsIn mice prone to diabetes, exendin‑4 increased insulin-producing cell mass.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell mass
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced beta-cell mass, and improved glucose tolerance.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 improved glucose tolerance.

    In plain wordsIn mice prone to diabetes, exendin‑4 improved glucose tolerance.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced beta-cell mass, and improved glucose tolerance.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 did not significantly change splenic CD4+ T-cell numbers.

    In plain wordsIn mice prone to diabetes, exendin‑4 did not significantly change CD4+ T-cell numbers in the spleen.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSplenic CD4+ T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 did not significantly change splenic CD8+ T-cell numbers.

    In plain wordsIn mice prone to diabetes, exendin‑4 did not significantly change CD8+ T-cell numbers in the spleen.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSplenic CD8+ T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 did not significantly change splenic B-cell numbers.

    In plain wordsIn mice prone to diabetes, exendin‑4 did not significantly change B-cell numbers in the spleen.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSplenic B cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 increased CD4+ T-cell numbers in lymph nodes.

    In plain wordsIn mice prone to diabetes, exendin‑4 increased CD4+ T-cell numbers in lymph nodes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLymph node CD4+ T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 increased CD8+ T-cell numbers in lymph nodes.

    In plain wordsIn mice prone to diabetes, exendin‑4 increased CD8+ T-cell numbers in lymph nodes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLymph node CD8+ T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 reduced CD4+CD25+Foxp3+ regulatory T-cell numbers in the thymus.

    In plain wordsIn mice prone to diabetes, exendin‑4 reduced regulatory T-cell numbers in the thymus.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseThymic regulatory T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese diabetic mice, exendin‑4 did not reduce CD4+CD25+Foxp3+ regulatory T-cell numbers in lymph nodes.

    In plain wordsIn mice prone to diabetes, exendin‑4 did not reduce regulatory T-cell numbers in lymph nodes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLymph node regulatory T cells
    Study

    mousen: not reported in source

    Nonobese diabetic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes.
    1 context sentence
    Summary · context
    We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 microg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.